Korea Reveals More On Plans To Grow Bioclusters At Osong And Daegu
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The Korean government announced more details on how it plans to cultivate its multibillion dollar, high-tech pharmaceutical R&D projects in Osong and Daegu
You may also be interested in...
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.
And The Winner Is? Two Cities For The Price Of One Win Bid For Multi-billion Dollar Korean Biopolis
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs named two cities - Osong and Daegu - as the winners of multi-billion-dollar, high-tech medical center sites planned in the country to draw multinational companies to the country
South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?
SEOUL - The South Korean government currently has no plans to implement compulsory licensing to help rein in costs for Korean patients being treated for fatal diseases, but will reconsider its stance should negotiations with industry break down, Jeon Jae-Hee, the Minister for Health, Welfare and Family Affairs said Feb. 23